Breaking Finance News

Evercore ISI upgraded ICON PLC (NASDAQ:ICLR) to Buy in a statement released earlier today.

Evercore ISI has upgraded ICON PLC (NASDAQ:ICLR) to Buy in a report released on Friday October 14, 2016.

On 9/28/2016, Zacks Investment Research released a statement for ICON PLC (NASDAQ:ICLR) bumped up the target price from $0.00 to $87.00 that indicated a possible upside of 0.13%.

Yesterday ICON PLC (NASDAQ:ICLR) traded 1.16% higher at $77.04. ICLR’s 50-day average is $76.59 and its two hundred day average is $72.29. With the last stock price up 7.80% relative to the two hundred day average, compared to the S&P 500 which has decreased -0.01% over the date range. Volume of trade was down over the average, with 62,981 shares of ICLR changing hands under the typical 380,491

Performance Chart


ICON PLC has a one year low of $62.31 and a one year high of $79.80 with a PE ratio of 18.02 ICON PLC’s market capitalization is presently $0.

A total of 11 firms have released a report on ICON PLC. Three brokerages rating the stock a strong buy, 4 firms rating the stock a buy, 7 brokers rating the stock a hold, zero equity analysts rating the company a underperform, and finally 2 analysts rating the company a sell with a 12-month price target of $77.36.


ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.